An international collaboration led by Hilleman Laboratories has confirmed the launch of a new oral cholera vaccine called HILLCHOL, hoping to address significant global shortages.
Just months after facing a rejection in the US, the bispecific antibody odronextamab (Ordspono) has been approved by the European Commission for the treatment of two types of blood cancer in patients that have failed to respond to previous treatments.
As antibody-drug conjugates (ADCs) continue to heat up in the industry, Adcendo of Denmark has gained the global rights from Multitude Therapeutics to develop the Chinese company’s ADC for the treatment of cancer outside of the Greater China region.
In a promising advancement, scientists from the University of North Carolina at Chapel Hill and Emory University have developed a novel drug delivery system using synthetic amyloid beta (Aβ) peptides.
In a groundbreaking development, a team of biochemical engineers from South Korea has unveiled a new exosome-based delivery system, termed MAPLEX, that holds the potential to transform treatments for various diseases, including Alzheimer’s.
The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organization’s declaration of mpox as a Public Health Emergency of International Concern (PHEIC) earlier this month.
The US FDA has granted approval to Niktimvo for the treatment of chronic graft-versus-host disease, a serious immune condition affecting the recipients of stem cell transplants.
Two months after placing a partial hold on a phase 1 clinical trial evaluating an antibody-drug conjugate (ADC) in cancer patients, the FDA is allowing the study to proceed with the lower doses of the treatment.
Katarina Wikstrom has worked for over 20 years in the field of translational molecular oncology and holds the position of VP global product development at Almac Diagnostic Services.
The agreement will give Genentech access to Sangamo’s capsid delivery platform and epigenetic regulation technology with applications in neurodegenerative disease.
In this Q&A, we delve into the collaboration between Skye Bioscience and Beacon Biosignals to enhance the evaluation of nimacimab, a promising treatment for obesity and its comorbid conditions, including obstructive sleep apnea (OSA).
BeiGene, a global oncology company, has announced the opening of its flagship US facility, which will expand the company’s biologics manufacturing capabilities and clinical research and development activities.
A committee from the European Medicines Agency (EMA) has voted against granting Leqembi (lecanemab) a marketing authorization due to the risk of serious side effects associated with the treatment.